Abstract
Tau aggregation is an appealing target for therapeutic intervention. However, conformational change or aggregation needs to be targeted without inhibiting the normal biology of tau and its role in microtubule stabilization. The number of compound classes being tested at this time are very limited and include Congo red derivatives [1], anthraquinones (Pickhardt et al. 2005 [2], disputed in Crowe et al. 2007 [3]), 2,3-di(furan-2-yl)-quinoxalines , phenylthiazolyl-hydrazide (PTH) [4], polyphenols and porphyrins [5] and cyanine dyes [6-8]. Herein we have utilized a member of the cyanine dye family (C11) in an organotypic slice culture model of tangle formation. Our results demonstrate that C11 is capable of affecting tau polymerization in a biphasic, dose dependent manner. At submicromolar concentrations (0.001 μM) C11 reduced levels of aggregated tau. However, higher doses resulted in an increase in tau polymerization. These effects can also be seen at the level of individual filaments with changes in filament length and number mirroring the pattern seen via immunoblotting. In addition, this effect is achieved without altering levels of phosphorylation at disease and microtubule binding relevant epitopes.
Keywords: Alzheimer disease, tau, tangle, cyanine, phosphorylation, polymerization
Current Alzheimer Research
Title: Disaggregation of Tau as a Therapeutic Approach to Tauopathies
Volume: 7 Issue: 3
Author(s): K. Duff, J. Kuret and E.E Congdon
Affiliation:
Keywords: Alzheimer disease, tau, tangle, cyanine, phosphorylation, polymerization
Abstract: Tau aggregation is an appealing target for therapeutic intervention. However, conformational change or aggregation needs to be targeted without inhibiting the normal biology of tau and its role in microtubule stabilization. The number of compound classes being tested at this time are very limited and include Congo red derivatives [1], anthraquinones (Pickhardt et al. 2005 [2], disputed in Crowe et al. 2007 [3]), 2,3-di(furan-2-yl)-quinoxalines , phenylthiazolyl-hydrazide (PTH) [4], polyphenols and porphyrins [5] and cyanine dyes [6-8]. Herein we have utilized a member of the cyanine dye family (C11) in an organotypic slice culture model of tangle formation. Our results demonstrate that C11 is capable of affecting tau polymerization in a biphasic, dose dependent manner. At submicromolar concentrations (0.001 μM) C11 reduced levels of aggregated tau. However, higher doses resulted in an increase in tau polymerization. These effects can also be seen at the level of individual filaments with changes in filament length and number mirroring the pattern seen via immunoblotting. In addition, this effect is achieved without altering levels of phosphorylation at disease and microtubule binding relevant epitopes.
Export Options
About this article
Cite this article as:
Duff K., Kuret J. and Congdon E.E, Disaggregation of Tau as a Therapeutic Approach to Tauopathies, Current Alzheimer Research 2010; 7 (3) . https://dx.doi.org/10.2174/156720510791050885
DOI https://dx.doi.org/10.2174/156720510791050885 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nerve Growth Factor, Stress and Diseases
Current Medicinal Chemistry Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Drug Metabolizing Enzymes in the Perinatal and Neonatal Period: Differences in the Expression and Activity
Current Drug Metabolism Diazenyl Derivatives as Therapeutic and Diagnostic Agents Acting on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Opioids Resistance in Chronic Pain Management
Current Neuropharmacology Measurement of myo-Inositol in Biological Systems by Mass Spectrometric and In Vivo 1H Magnetic Resonance Spectroscopic Techniques
Current Organic Chemistry More Evidence for the Therapeutic Role of Pramipexole in Upper Limb Restlessness Due to Cervical Disc Pathology?
Current Clinical Pharmacology Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Cucurbituril Complexes of Redox Active Guests
Current Organic Chemistry An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice
Central Nervous System Agents in Medicinal Chemistry Nitric Oxide is a Key Molecule Serving as a Bridge between Radiation-Induced Bystander and Adaptive Responses
Current Molecular Pharmacology The Functional Role of CYP2B6 in Human Drug Metabolism: Substrates and Inhibitors In Vitro, In Vivo and In Silico
Current Drug Metabolism Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets Cognitive Mechanisms in Decision-Making in Patients With Mild Alzheimer Disease
Current Alzheimer Research Mitochondrial Membrane Lipids in Life and Death and their Molecular Modulation by Diet: Tuning the Furnace
Current Drug Targets New Ketonethiosemicarbazones for Melanogenesis Inhibition
Current Bioactive Compounds Non-Neuronal Cell Modulation Relieves Neuropathic Pain: Efficacy of the Endogenous Lipid Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets